Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 11
Future Directions and Unmet Needs in HR+ Breast Cancer
The key opinion leaders discuss the current unmet needs in the management of HR+/HER2- metastatic breast cancer and explore potential future directions and strategies that may lead to improved patient outcomes.
- Looking ahead, what are the key remaining unmet needs and future directions to improve outcomes for HR+/HER2- mBC patients with ESR1 and other mutations driving endocrine resistance?
- What novel targets and therapeutic strategies are being explored preclinically and in early trials?